Clinical trials
First-Line clinical trials
Below are recruiting first-line clinical trials, each written for real people, not researchers. We’re tracking 399 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06840782RecruitingPhase 3
Immunotherapy plus local treatments for early spread lung cancer
This trial tests whether adding local treatments like radiation or surgery to standard immunotherapy can help people with lung cancer that has spread to a few spots. It aims to see if this combination improves control of the disease.
Creil, Hauts-de-FranceAges 18 years+ - NCT06841705RecruitingPhase 2
Early vedolizumab as first treatment for colitis from immunotherapy
This trial tests if giving vedolizumab early can help control severe diarrhea and colon inflammation caused by immunotherapy (a type of cancer treatment). It may offer a new option for people who develop these side effects.
Boston, MassachusettsAges 18 years+ - NCT05862259Recruiting
Immunotherapy as first treatment for advanced stage IV cancers
This study looks at whether immune checkpoint inhibitors given as the first treatment work well and are safe for people with advanced (stage IV) solid tumors. You might qualify if you can take study treatment reliably and your cancer type and health match the study rules.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06819007RecruitingPhase 3
Study of trastuzumab deruxtecan plus bevacizumab for HER2-positive ovarian cancer
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
Burbank, CaliforniaAges 18 years+ - NCT05173246RecruitingPhase 2
First-line treatment study for advanced small cell esophageal cancer
This Phase 2 trial tests JS001 plus TP as a first treatment for people with advanced or unresectable small cell esophageal cancer. It aims to see how well this combination controls the cancer and improves outcomes compared with starting treatment with standard options.
Guangzhou, GuangdongAges 18–75 - NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75 - NCT06792994Recruiting
CLL treatment sequence study for patients in GCLLSG trials
This observational study looks at the order of treatments given to people with chronic lymphocytic leukemia (CLL) who took part in certain first-line studies run by the German CLL Study Group. It aims to learn how different treatment sequences affect overall survival over time.
CologneAges 18–99 - NCT06801665RecruitingPhase 2
Combination therapy for advanced colorectal cancer with liver spread
This trial tests a new combination of treatments for advanced colorectal cancer that has spread to the liver. It aims to see if this combination can shrink tumors and help patients live longer.
ChangzhouAges 18–75 - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Birmingham, AlabamaAges 18 years+ - NCT06277154RecruitingPhase 2
MASCT-I plus chemo for first-line advanced soft tissue sarcoma
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
GuangzhouAges 18–70 - NCT06775743RecruitingPhase 2
Combination therapy and radiation for EGFR-mutant lung cancer after resistance
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Chandler, ArizonaAges 18 years+ - NCT06767813RecruitingPhase 2
Study of TQB2868, anlotinib, and chemo for first-line pancreatic cancer
This trial tests a new combination of drugs (TQB2868, anlotinib, and chemotherapy) as a first treatment for metastatic pancreatic cancer that has spread. It may help if you have not had prior treatment for advanced disease.
Zhengzhou, HenanAges 18–75 - NCT06767527RecruitingPhase 3
AK112 plus chemo for first-line triple-negative breast cancer
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
BeijingAges 18–75 - NCT06770452RecruitingPhase 2
HRS-4642 combo for first-line advanced pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hangzhou, ZhejiangAges 18–75 - NCT06755515Enrolling by invitationPhase 2/Phase 3
Rulonilimab + Chemo for Advanced Cervical Cancer
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
Linyi, ShandongAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Jonesboro, ArkansasAges 18 years+ - NCT05969171RecruitingPhase 2
Surufatinib plus chemotherapy for advanced pancreatic cancer
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
ShanghaiAges 18–75 - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
New Haven, ConnecticutAges 18 years+ - NCT06730373RecruitingPhase 2
RC48 plus immunotherapy and chemotherapy for advanced stomach cancer
This study tests a combination of three treatments for advanced stomach cancer that is HER2-positive. The treatments are RC48, an antibody-drug conjugate that targets HER2 on cancer cells, sintilimab, which helps the immune system fight cancer, and S-1, a chemotherapy drug. The goal is to see if the combination is safe and effective as a first-line treatment.
Zhengzhou, HenanAges 18–75 - NCT06738160RecruitingPhase 2
Combination therapy for advanced lung cancer with bone metastases
This trial tests a new combination of drugs and radiation to improve the effects of first-line chemotherapy and immunotherapy for patients with advanced non-small cell lung cancer that has spread to the bones. The goal is to help shrink tumors and potentially improve overall outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05442060RecruitingPhase 2
Test medicine add-on to erlotinib for EGFR lung cancer
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
Taipei, Beitou DistrictAges 20 years+ - NCT06725368RecruitingPhase 2
Chemo plus cetuximab after pembrolizumab for head and neck cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Ars-LaquenexyAges 18 years+ - NCT06699212RecruitingPhase 3
Light-activated therapy with immunotherapy for head and neck cancer
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+
Hear when a new First-Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line?
- Yes. Clin2 currently lists 399 recruiting first-line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.